跨性别患者的前列腺特异性抗原筛查
本文为非系统性叙述性综述,检索截至2022年6月的PubMed文献,评估跨性别女性前列腺癌发病率与前列腺特异性抗原(PSA)筛查的现有认识。主要学会均无跨性别女性PSA筛查共识,指南 largely 缺失该人群;病例报告提示跨性别女性前列腺癌可能更具侵袭性,或为性别肯定激素治疗前已存在或去势抵抗。
要点
- 主要学会均无跨性别女性PSA筛查共识,指南 largely 缺失该人群。
- 病例报告提示跨性别女性前列腺癌可能更具侵袭性。
- 需进一步研究以建立该人群筛查指南。
核心结论
- 我们对跨性别女性PSA筛查的认识尚处于初期阶段。
- 未来研究的重要方向包括理解PSA筛查的风险与获益、减轻筛查潜在负面心理效应、建立接受性别肯定激素治疗者的基线PSA值及界定「升高」值、确定开始筛查时机及验证生物标志物准确性。
研究设计与样本
- 非系统性叙述性综述,检索截至2022年6月的所有PubMed出版物,遵循PRISMA声明。
- 鉴于该主题原始研究有限,亦纳入病例报告。
主要发现
- 跨性别女性即使接受性别肯定手术后仍保留前列腺,因此需持续筛查前列腺癌。
- 病例报告数据提示跨性别女性前列腺癌可能更具侵袭性,且这些癌症可能在性别肯定激素治疗前已存在或为去势抵抗。
关键数值与推荐
- 原文未报告具体筛查阈值、剂量或推荐等级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Approximately 0.4-1.3% of the worldwide population is transgender. Although the exact prevalence is unknown, there is an increase in open identification as transgender. Among transgender women (TW), the prostate is retained even after gender-affirmation surgery, thus necessitating ongoing screening for prostate cancer (CaP). However, little is known about CaP screening in this population. OBJECTIVE: To assess our current understanding of CaP incidence and prostate-specific antigen (PSA) screening in TW. EVIDENCE ACQUISITION: We performed a nonsystematic narrative review of all PubMed publications through June 2022 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. Given the limited primary research on this subject, case reports were also included. Studies were reviewed to understand PSA screening practices and reports of CaP in this population, as applicable. EVIDENCE SYNTHESIS: There is no consensus regarding PSA screening in TW from any of the major societies, and TW are largely absent from guidelines. Case report data suggest that TW with CaP may have more aggressive disease, and these cancers may have been pre-existing prior to present before gender-affirming hormone therapy (GAHT) or be castrate-resistant. CONCLUSIONS: We are in the infancy of our understanding of PSA screening in TW. Important avenues for future research include understanding the risks/benefits of PSA screening in TW, how best to mitigate potential negative psychological effects of PSA screening in TW, establishing baseline PSA values for those on GAHT (and determining what values should be considered "elevated"), establishing when to initiate PSA screening for those on GAHT, and establishing the accuracy of biomarkers for those undergoing GAHT. PATIENT SUMMARY: We examined patterns of prostate cancer screening for transgender women. Little is known about prostate cancer incidence or screening in this population. Additional research is needed to establish guidelines for screening in this population.
引用
- Nik-Ahd F, Jarjour A, Figueiredo J, et al. Prostate-Specific Antigen Screening in Transgender Patients. Eur Urol. 2022. PMID: 36344317. doi:10.1016/j.eururo.2022.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。